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Recent data from the AZURE, ABCSG-12, and ZO-FAST clinical trials have challenged our understanding of the
potential anticancer activity of zoledronic acid (ZOL). Although the results of these studies may appear to be conﬂicting
on the surface, a deeper look into commonalities among the patient populations suggest that some host factors (i.e.
patient age and endocrine status) may contribute to the anticancer activity of ZOL. Indeed, data from these large clinical
trials suggest that the potential anticancer activity of ZOL may be most robust in a low-estrogen environment. However,
this may be only part of the story and many questions remain to be answered to fully explain the phenomenon. Does
estrogen override the anticancer activity of ZOL seen in postmenopausal women? Are hormones other than estrogen
involved that contribute to this effect? Does the role of bone turnover in breast cancer (BC) growth and progression
differ in the presence of various estrogen levels? Here, we present a review of the multitude of factors affected by
different endocrine environments in women with BC that may inﬂuence the potential anticancer activity of ZOL.
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introduction
Recent clinical trial data have challenged our understanding of
the potential anticancer activity of zoledronic acid (ZOL).
Speciﬁcally, the AZURE, ABCSG-12, and ZO-FAST studies are
large clinical trials that have reported on the potential
anticancer activity of ZOL in women with breast cancer (BC).
Although the results of these studies appear confounding at
ﬁrst glance, a deeper look into commonalities of the speciﬁc
patient populations provides clues regarding host factors (i.e.
patient age and endocrine status) that may contribute to the
optimal anticancer activity of ZOL.
For example, the AZURE trial evaluated the potential
anticancer effects of ZOL in combination with standard
adjuvant therapy (i.e. chemotherapy and endocrine therapy) in
pre- and postmenopausal women with early (stage II/III) BC
(N = 3360). This heterogeneous group received standard
adjuvant therapy (chemotherapy±endocrine therapy) plus a
tapered dosing schedule of ZOL (4 mg every 3–4 weeks ×6; 4
mg every 3 months ×8; 4 mg every 6 months ×5). Although
the primary end point of disease-free survival (DFS) was not
met in the overall patient population, prospective subgroup
analyses showed that ZOL signiﬁcantly improved invasive DFS
by 25% [hazard ratio (HR) = 0.75; P = 0.02] and overall survival
(OS) by 26% (HR = 0.74; P = 0.04) in women who were more
than 5 years postmenopausal at study entry (n = 1041) [1].
In contrast with the AZURE study, only premenopausal
women (median age, 45 years) with endocrine-responsive
early-stage BC undergoing ovarian suppression (N = 1803)
were enrolled in ABCSG-12 [2]. However, the endocrine status
of these women was likely similar to those in the
postmenopausal subgroup in the AZURE trial. Indeed, in
premenopausal women, ovarian suppression with a luteinizing
hormone (LH)-releasing hormone agonist (e.g. goserelin)
decreases circulating estrogen to postmenopausal levels for the
duration of treatment and may have long-term efﬁcacy [3]. In
fact, all of the women in ABCSG-12 experienced endocrine
therapy-induced artiﬁcial menopause due to goserelin therapy
for 3 years. Moreover, half of these patients also received
anastrozole [2], an aromatase inhibitor (AI) that might have
depressed estrogen levels further.
Notably, the results from ABCSG-12 showed that the
addition of ZOL to adjuvant endocrine therapy signiﬁcantly
improved DFS (HR = 0.72; P = 0.014) and OS (HR = 0.63;
P = 0.049) at 84 months’ median follow-up, and reduced
recurrences both in and outside of bone [4]. In addition,
preplanned subgroup analyses based on age (≤40 years or >40
years) showed that ZOL signiﬁcantly improved DFS by 34% in
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women over 40 years of age (n = 1390; HR = 0.66; P = 0.013).
However, ZOL did not improve the DFS in women who were
40 years of age or younger (n = 413) [4]. These data support
previously published reports showing that women over 40
years of age may achieve more complete estrogen suppression
[5–8]. Furthermore, chemotherapy-induced amenorrhea has
been reported to occur less frequently in women less than 40
years of age compared with those over 40 [5, 6].
Similar results were observed in the ZO-FAST trial, in which
postmenopausal women receiving adjuvant letrozole therapy
for stage I–III BC (N = 1065) received ZOL (upfront versus
delayed-start ZOL) to prevent AI-associated bone loss [9, 10].
After 60 months’ median follow-up, the addition of upfront
ZOL to AI therapy was associated with a 34% reduction in the
risk of DFS events (disease recurrence or death) compared with
delayed ZOL (HR = 0.66; P = 0.0375) [10]. It should be noted
that this signiﬁcant improvement in DFS also was observed in
a low-estrogen environment. Indeed, AIs (i.e. anastrozole and
letrozole) reduce circulating estrogens to levels substantially
lower than those observed after natural menopause [11].
Moreover, letrozole, the AI used in the ZO-FAST trial, reduces
estradiol levels to a greater extent than anastrozole in
postmenopausal women [11, 12].
Taken together, these data provide supporting evidence that
the possible anticancer activity of ZOL may be most robust in
a low-estrogen environment. However, this may be only part of
the story, and many questions remain to be answered before
the phenomenon can be fully explained. Does estrogen
override the anticancer activity of ZOL seen in postmenopausal
women with BC? With 200–300 estrogen-response genes in the
human genome [13, 14], can the responsible pathways be
narrowed down? Do hormones other than estrogen modulate
ZOL’s potential anticancer effect in this patient population?
Does the role of bone turnover in BC tumor growth and
progression change in response to different estrogen levels?
Another issue that confounds interpretation of available data
from clinical studies is deﬁning endocrine status. There is no
standard deﬁnition of ‘postmenopausal’ to enable the
comparison of between-trial results, and estrogen levels were
not repeatedly measured in the majority of BC clinical trials.
Other important questions also remain unanswered. For
example, how closely do animal models of a low-estrogen
environment (e.g. ovariectomy and pharmacologic aromatase
inhibition) mimic the postmenopausal status in women with
BC? Endocrine systems differ between humans and animals,
making the clinical relevance of preclinical results unknown.
Although we cannot answer all questions at this time, an
extensive review of the literature has provided insight into the
complex interplay between the bone microenvironment, the
endocrine system, and antiresorptive therapies that may help to
clarify the clinical trial data reported to date.
nitrogen-containing bisphosphonates
and bone
Nitrogen-containing bisphosphonates (N-BPs) affect a
multitude of cellular pathways important for cell growth and
differentiation. These pathways likely modulate the
multifactorial mechanism of action of ZOL-mediated
anticancer activity. Bisphosphonates (BPs) are cleared rapidly
from the blood stream via avid binding to mineralized bone
surfaces undergoing active remodeling and by renal ﬁltration of
unbound drug [15]. Furthermore, as these agents do not
readily cross the plasma membrane, the intracellular
concentration of BPs in most tissues is very low [16]. This
combination of properties leads to BPs accumulating only in
those cells that exhibit ﬂuid-phase endocytosis, such as
osteoclasts, macrophages [17, 18], and monocytes [19]. Thus,
in addition to targeting bone remodeling, BPs can potentially
affect other tissues through accumulation within other cells,
especially those of the immune system. Notably, human
cancer cell lines (e.g. BC, prostate cancer, and myeloma)
also have been shown to internalize BPs by ﬂuid-phase
endocytosis [20].
Once internalized, N-BPs inﬂuence multiple pathways and
effectively inhibit osteoclast-mediated bone resorption through
inhibition of the mevalonate pathway (Figure 1) [21]. This is
an important biochemical pathway involved in the production
of cholesterol and isoprenoids, which are required for
maintaining cell-membrane integrity, producing steroids, and
regulating cellular metabolism. Furthermore, isoprenyl
precursors are crucial for the prenylation of regulatory proteins
involved in the control of cell proliferation, tumor progression,
and cell death induced by anticancer therapies. These factors
suggest that inhibition of the mevalonate pathway may have an
effect on cellular activities that goes beyond inhibition of bone
resorption (i.e. anticancer activity).
The major molecular target inhibited by all N-BPs is
farnesyl pyrophosphate synthase (FPPS), an enzyme in the
mevalonate pathway [22]. Geranylgeranyl pyrophosphate
synthase (GGPPS), another downstream component of the
mevalonate pathway, also has been shown to be inhibited,
although less actively, by ZOL [23]. Inhibition of FPPS and
GGPPS causes a reduction in the posttranslational prenylation
of small guanosine triphosphatases (GTPases) (‘G proteins’;
e.g. Ras, Rho, and Rac), which are key components of many
intracellular signaling pathways and play key roles in cell
proliferation and survival. As a result, inhibition of prenylation
leads to loss of cellular functions and induces apoptosis.
The biochemical effects of N-BPs may not be limited to the
mevalonate pathway, and modulation of other pathway
components, such as inhibition of kinases and phosphatases,
cannot be excluded. Although little direct evidence is available,
these putative additional biochemical effects of N-BPs appear
intuitive from their chemical structure. Moreover, the effects of
N-BPs on osteoclast-mediated bone resorption and several
anticancer effects (e.g. decreased cancer cell viability,
proliferation, adhesion and invasion, modulation of endothelial
cell function and angiogenesis, and decreased macrophage
activity) are closely correlated with FPPS inhibition. Therefore,
potential mechanisms of action for the likely anticancer activity
of N-BPs, including ZOL, may act through modulation of
several complex biochemical pathways downstream of FPPS
inhibition. Indeed, numerous studies have demonstrated
potential anticancer activity of BPs in preclinical BC model
systems [24, 25] (supplementary Table S1, available at Annals
of Oncology online).
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In preclinical model systems, ZOL was the most potent
inhibitor of FPPS activity among the N-BPs tested, and
correlated with the greatest antiresorptive activity in vitro and
in vivo [19, 22, 25]. In addition to inhibiting FPPS, N-BPs have
been shown to induce the production of an intracellular
adenosine triphosphate analogue (triphosphoric acid 1-
adenosin-50-yl ester 3-(3-methylbut-3-enyl) ester [ApppI])
that can directly induce cellular apoptosis and modulate the
immune response [20]. As a result, N-BPs interfere with
multiple cellular functions required for the bone-resorbing
activity and survival of osteoclasts. Moreover, the cellular
functions affected by N-BPs may also be involved in cancer cell
growth as well as osteoclast survival. Additionally, a multitude
of other factors in and outside of the bone microenvironment
may inﬂuence the relative activity of ZOL.
It should be noted that preclinical studies have shown that
ZOL inhibits osteoclast activity in animal models of both
benign and malignant disease regardless of gender or
endocrine status (i.e. estrogen-deﬁcient compared with normal
females) [26–50]. It is well established that ZOL potently
inhibits osteoclast-mediated bone resorption in female animals
rendered estrogen-deﬁcient via ovariectomy or aromatase
inhibition [26–29], similar to the endocrine environment of
postmenopausal women receiving ZOL to maintain bone
health in the osteoporosis or adjuvant BC settings. However,
preclinical studies also have shown ZOL to be equally effective
in nonmalignant male and nonovariectomized female animal
models [31–37], suggesting that ZOL-mediated osteoclast
inhibition is independent of the hormone environment.
Furthermore, the potential anticancer activity of ZOL has been
demonstrated in malignant tumor models in both male and
nonovariectomized female animals [38–50]. It should be noted
that most experiments use young animals with inherently high
rates of bone turnover, a markedly different bone environment
from that found in premenopausal women. These data suggest
that additional factors independent of osteoclast inhibition
may contribute to the anticancer activity of ZOL observed in
AZURE, ABCSG-12, and ZO-FAST.
In the clinical setting, ZOL has been shown to improve bone
mineral density (BMD) in men and women with cystic ﬁbrosis
[51], women with postmenopausal osteoporosis [52, 53], and
premenopausal women receiving adjuvant chemotherapy for
BC [54–56]. Thus, ZOL-mediated osteoclast inhibition and
subsequent bone resorption appear to be independent of
estrogen levels. Combined with the results of the AZURE and
ABCSG-12 trials, these preclinical and clinical data imply that
ZOL may affect other cell types or pathways modulated by
estrogen levels [57]. Because ZOL rapidly binds to bone and
soft tissue exposure is low, these target cells may be residing in
bone marrow (e.g. dormant tumor cells and endothelial
precursor cells) or could be cells that can efﬁciently internalize
ZOL (e.g. macrophages and monocytes).
bone microenvironment
Although the cellular and molecular mechanisms by which a
cancer cell undergoes metastasis are largely unknown, studies
show that bone marrow produces a number of growth factors
and cytokines that attract cancer cells [58–60]. These factors
are secreted by bone marrow-derived stem cells in the bone
microenvironment, providing a supportive niche that facilitates
cancer cell survival and proliferation [61, 62]. Furthermore, the
molecular interactions between the bone marrow
microenvironment and cancer cells may shield cancer cells
from cytotoxic chemotherapy, allowing them to remain
dormant for extended periods of time before becoming active
and metastasizing to secondary sites [58–62]. As a result, the
bone marrow acts as a sanctuary for cancer cells, which
can contribute to subsequent relapse in bone and other
sites [61, 62].
The potential anticancer activity of ZOL may be mediated
through its effects on the bone marrow microenvironment,
Figure 1. The mevalonate pathway is important in the synthesis of cholesterol, and of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate
(GGPP), which provide the farnesyl and geranylgeranyl groups, respectively, for protein prenylation. Reproduced from Shipman et al. [21].
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macrophages, and myeloid-derived suppressor cells, and may
be independent of its osteoclast-inhibition activity [40, 43, 49].
Speciﬁcally, ZOL may impede the development of bone
metastases by rendering the bone microenvironment less
conducive to cancer cell survival and proliferation [19, 22, 25].
Furthermore, the role of bone marrow-derived stem cells in the
development of extraskeletal metastases might be inﬂuenced by
a patient’s endocrine status, and the ability of ZOL to help
maintain cancer cell dormancy in bone marrow may be
counteracted by various hormones in premenopausal women.
This hypothesis is supported by the subset analyses in
postmenopausal women in the AZURE study, which showed
that the potential anticancer activity of ZOL observed in this
patient population occur outside of bone. Only a weak,
nonsigniﬁcant effect on bone recurrence was observed
irrespective of menopausal status, with all of the anticancer
activity observed in postmenopausal women occurring outside
of bone [1].
impact of hormones on the bone
microenvironment
A number of hormones in addition to estrogens (estradiol,
estriol, and estrone) and progesterone are involved in
regulating ovarian function in women. These include follicle-
stimulating hormone (FSH), LH, activins, inhibins, follistatin,
anti-Müllerian hormone (AMH), bone morphogenetic protein
(BMP), and androgens [testosterone, androstenedione, and
dehydroepiandrosterone sulfate (DHEAS)]. Some of these
hormones, such as activins, inhibins, BMPs, and androgens,
also have important effects on bone. Indeed, DHEAS has been
shown to suppress secretion of the bone resorption-promoting
cytokine, interleukin (IL)-6, by human bone marrow cells
obtained from postmenopausal women [63]. Furthermore,
activins, inhibins, and BMPs belong to the transforming
growth factor-β (TGF-β) superfamily of growth and
differentiation factors, which are known to inﬂuence bone
physiology [64].
Several TGF-β family members (e.g. BMPs, TGF-β1, TGF-
β2, and TGF-β3) are involved in bone remodeling [65, 66] and
have been shown to induce osteoblast replication in culture
[65]. Although, however, AMH belongs to the TGF-β
superfamily, it is unknown if this hormone is involved in bone
remodeling [67]. Studies have shown that TGF-β1-3 can
enhance collagen and noncollagen protein synthesis in bone,
increase production of proteoglycans, enhance differentiation
of mesenchymal cells, and increase replication of chondroblasts
[65, 66]. In contrast with its effects in undifferentiated cells,
TGF-β is known to decrease cell proliferation and function in
differentiated cells [65]. Studies also have shown that TGF-β
stimulates IL-6 and IL-11 secretion from bone marrow stromal
cells in culture [68]. This is of interest because IL-6 has been
shown to enhance estrogen receptor-α-positive (ERα+) BC cell
line (MCF-7) growth [69]. Furthermore, bone marrow-derived
cytokines (e.g. IL-6) and related factors have been shown to affect
BC metastasis, and preclinical evidence suggests that bone
marrow-derived cytokines may enhance tumor cell proliferation,
survival, and invasiveness [69–71]. Together, these data suggest
that TGF-β can stimulate BC cell growth via IL-6.
Examining the pathways affected by members of the TGF-β
superfamily can be complex, as family members often regulate
the activity of one another. For example, betaglycan, a TGF-β
type III receptor, is a membrane-anchored proteoglycan
receptor that binds TGF-β1, TGF-β2, inhibin A, and BMP-2,
-4, and -7, thereby modulating their actions [72–74].
Moreover, inhibins, follistatin, and BMP-3 are receptor
antagonists that can block BMP signaling in bone, which
modulates osteoblast and osteoclast development [75–77].
Notably, inhibin A in particular has been shown to inﬂuence
bone health in women regardless of menopausal status [78].
Serum inhibin levels inversely correlate with bone-formation
and bone-resorption markers in pre- and perimenopausal
women and across the menopause transition, with bone
turnover increasing as inhibin levels fall [75, 78]. Inhibins bind
to cells during osteoblastogenesis and osteoclastogenesis and
can block BMP-stimulated osteoblast and osteoclast
development [75]. Furthermore, continuous in vivo exposure
of gonadectomized mice to inhibin A is anabolic, and cycling
inhibin exposure suppresses bone turnover, suggesting a
bimodal mechanism of action for endocrine regulation of bone
metabolism [75]. Moreover, an inducible human inhibin A
transgenic mouse model showed that this hormone increased
BMD and bone volume, and prevented gonadectomy-
associated loss of BMD and bone volume [79].
Estrogen, a primary regulator of ovarian function, is also
known to affect bone health in women [68, 75, 80–84]. One
mechanism by which the estrogen estradiol may act on bone is
through a pathway involving the receptor activator of nuclear
factor-kappa B (RANK), RANK ligand (RANKL), and
osteoprotegerin (OPG) in which RANKL induces osteoclast
activity and OPG is a physiologic inhibitor of RANKL [85–88].
Studies in mouse models have shown that inactivation of ERα
causes increased expression of RANKL and decreased
expression of OPG [86]. These results have been conﬁrmed in
other mouse studies, which showed that withdrawal of estradiol
reduced OPG levels while addition of estradiol increased OPG
levels [87, 88]. Therefore, the loss of estradiol leads to
increased osteoclast-mediated bone resorption subsequent to
elevated levels of RANKL and decreased levels of OPG.
These data highlight the effect of estrogen deﬁciency on
bone turnover and add to the hypothesis that estrogen
deprivation enhances all aspects of bone turnover. Moreover,
in a small study of patients with cancer (N = 49) ZOL therapy
decreased RANKL expression by 22% and increased OPG
expression by 96%, thereby altering the RANKL/OPG ratio in
favor of bone formation [89]. Creating a less hospitable
microenvironment in bone for cancer cell growth through
bone turnover suppression, in addition to possible direct
anticancer effects of BPs, may be a potential mechanism for
the improved DFS observed with ZOL in the AZURE, ABCSG-
12, and ZO-FAST trials.
hormonal transitions during early and
late menopause
It is evident from the literature that hormones and cytokines
involved in ovarian function also contribute to the dynamic
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bone microenvironment. However, the extent to which each of
these factors contributes to various processes differs based on
menopausal status. Natural menopause is the permanent end
of menstruation due to cessation of ovarian follicular activity
(i.e. the absence of oocytes in the ovaries) [90]. Cancer
therapies (i.e. chemotherapy and endocrine therapy) can
induce artiﬁcial menopause, which may be temporary. Notably,
a confounding factor in using data from several of the large BC
clinical trials is that each study used different, and often vague,
deﬁnitions of ‘postmenopausal’ (Table 1) [1, 2, 9, 91–93].
Indeed, the term ‘postmenopausal’ is imprecise and can lead to
confusion. To clarify, the events leading to and immediately
following natural menopause can be divided into several stages:
perimenopause, the menopausal transition, and menopause.
Perimenopause refers to the time when the endocrine, biologic,
and clinical features of menopause begin, which can be any
time from several years before menopause to 1 year after the
ﬁnal menses [90]. The menopausal transition refers to the
portion of perimenopause up to the ﬁnal menses, whereas
postmenopause refers to the time 12 months after the ﬁnal
menses. Levels of hormones involved in ovarian function vary
greatly during each of these stages.
Hormones that vary during perimenopause include AMH,
estradiol, FSH, LH, and inhibins A and B. Serum levels of
AMH, which are detectable from before birth through
menopause, decline continuously with age in healthy women
and become undetectable after menopause [67]. Low and
rapidly declining AMH serum levels directly correlate with
ovarian follicle reserves, making it a useful marker for ovarian
function [67]. Notably, serum levels of AMH are elevated in
women with polycystic ovary syndrome but are very low in
women with ovarian failure. Thus, AMH can act as a marker
of ovarian function in women approaching natural menopause
and in women with cancer therapy-induced artiﬁcial
menopause.
Other hormones (i.e. estradiol, FSH, and LH) regulating
ovarian function have more complicated patterns during
perimenopause because their levels also ﬂuctuate during the
menstrual cycle. However, overall, serum FSH and LH levels
increase as inhibin B levels decrease during the menopausal
transition [90, 94]. Changes in these hormone levels are linked
to age, as progressive increases in serum FSH levels have been
observed with increasing age in regularly cycling women over
40 years of age. Furthermore, it appears that inhibin B levels
drop when the remaining ovarian follicles have reached a
critically low number. During peri- and postmenopause, FSH
and LH levels rise. In contrast, estradiol levels remain relatively
constant until late perimenopause [90]. However, after the ﬁnal
menses, during late perimenopause and early postmenopause,
estradiol levels decline rapidly, only stabilizing 2–3 years after
menopause [95, 96].
Complicating matters further, after menopause and the
subsequent loss of ovarian estrogen production, the enzyme
aromatase converts circulating adrenal androgens (testosterone
and androstenedione) to estrogens in peripheral tissues (e.g.
breast, adipose, brain, and muscle) [97]. However, androgen
levels (i.e. testosterone, androstenedione, and DHEAS) remain
stable throughout perimenopause, although they do decline
with age [90, 97]. Despite these overall trends, serum estradiol
and inhibin (A and B) concentrations may ﬂuctuate widely in
individual women during the menopausal transition. The
general overall changes in FSH, inhibins A and B, and estradiol
Table 1. Deﬁnitions of menopause at study entry in adjuvant breast cancer clinical trials
Study (N) Not menopausal (n) Postmenopausal (n)
AZURE [1] (N = 3360) Premenopausal, ≤5 years after ﬁnal menses, or of
unknown menopausal status (n = 2318)
>5 years after ﬁnal menses (n = 1041)
ABCSG-12 [2] (N = 1803) Premenopausal: All patients developed
amenorrhea due to ovarian suppression with
goserelin
Not deﬁned (none)
ZO-FAST [9] (N = 1065) Premenopausal (none) Established = Age ≥55 years and natural cessation of mensesa
Recent = Age <55 years and cessation of menses induced by chemotherapy
or LHRH suppression: Amenorrheic <1 year and LH and FSH >40 iu/L
or estradiol <5 ng/dL; or amenorrheic ≥1 yeara
ATAC [91] (N = 9366) Premenopausal (none) Bilateral oophorectomy, OR >60 years of age, OR 45–59 years of age with
an intact uterus and ≥12 months of amenorrhea
For <12 months of amenorrhea (including history of hysterectomy or
HRT), FSH required to be within ‘postmenopausal range’
BIG 1–98 [92] (N = 8010) Premenopausal (n = 23, ineligible) Cessation of menses:
Before chemotherapy (n = 7692)
After chemotherapy (n = 192)
Uncertain or unknown menstrual status (n = 103)
TEAM [93] (N = 9766) Premenopausal (none) Cessation of menses:
<50 years (n = 331)
50–59 years (n = 3017)
>60 years (n = 6418)
FSH, follicle-stimulating hormone; HRT, hormone-replacement therapy; LH, luteinizing hormone; LHRH, luteinizing hormone-releasing hormone.
aDeﬁnitions are based on Novartis Pharmaceuticals Corporation data on ﬁle.
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levels during pre-, peri-, and postmenopause are depicted in
Figure 2 [90, 98].
We already know that there is a constant interplay between
the bone microenvironment, the endocrine system, and
menopausal status. For example, high-serum FSH is associated
with postmenopausal bone loss, and these effects are likely
independent of estrogen [99]. Haploinsufﬁcient FSHβ+/− mice
with normal ovarian function have increased bone mass and
decreased osteoclastic resorption, suggesting that FSH-
mediated effects on bone remodeling are estrogen independent
[99]. Thus, osteoclast-mediated bone resorption increases with
rising FSH levels during peri- and postmenopause. Another
study showed that, in women over 60 years of age, estradiol is
associated with the conversion of thick trabeculae into thinner,
but more numerous, trabeculae, thereby altering the
microstructure of trabecular bone [100]. Furthermore, age and
estrogen status, two other mediators of bone metabolism,
correlate with cytokine secretion by the bone marrow [68]. As
a result, bone health in women is tightly linked to ovarian
function and endocrine status.
The effects of the endocrine system on bone health may
extend to inﬂuences of the bone microenvironment on BC
growth and progression. Menopause and related hormonal
changes inﬂuence cytokine and growth factor production by
bone marrow cells. These factors may play important direct or
indirect roles in modulating the survival, invasion, and
adhesion of disseminated tumor cells. Indeed, several studies
show that cytokine (e.g. IL-6 and TGF-β) secretion by bone
marrow stromal cells is inﬂuenced by menopausal status [63,
68, 80, 83, 101]. These studies provide insight into how
hormonal changes during the menopausal transition might
alter the bone marrow microenvironment for BC recurrence.
Because of this, it is conceivable that many of these factors
have undeﬁned roles that may inﬂuence the efﬁcacy of ZOL in
various patient populations.
discussion
The ﬁndings of the AZURE, ABCSG-12, and ZO-FAST subset
analyses suggest that hormonal effects on the bone
microenvironment may play a substantial role in determining
who may beneﬁt most from adjuvant ZOL therapy. Current
clinical data suggest that both hormone suppression and
reduction of bone-turnover–derived growth factors are needed
for sufﬁcient suppression of dormant micrometastases in
patients with early-stage BC. In retrospect, given the number of
cellular pathways affected by the mevalonate pathway, TGF-β
family members, and hormones affected by menopause, it is
not surprising that the likely anticancer effects of ZOL, in and
outside of bone, may be modulated by the patient’s endocrine
environment. Because some of the hormones involved in
ovarian function also modulate bone health (e.g. activins,
inhibins, and BMPs), these hormones also may inﬂuence the
observed anticancer activity of ZOL in patients with BC.
Clinical studies examining the endocrine proﬁles of women
receiving ZOL during adjuvant BC therapy may help elucidate
the role of the patient’s endocrine environment.
The multitude of biochemical pathways that may be
inﬂuenced by estrogen is an additional complication. Indeed,
∼200–300 estrogen-responsive genes have been identiﬁed in
the human genome, suggesting a vast number of potential
functions for estrogen [13, 14]. Studies examining estrogen-
regulated pathways that may affect potential ZOL-mediated
anticancer activity in women with BC could lead to a better
understanding of its mechanism of action in this setting.
Furthermore, the growth and differentiation factor TGF-β and
small GTPases, the prenylation of which is controlled by the
mevalonate pathway, are involved in regulating each other in
various pathways [102–105]. This suggests that inhibition of
the mevalonate pathway with ZOL also may inﬂuence TGF-β–
mediated pathways. Finally, it is also possible that the potential
anticancer effects of ZOL are masked in a high-estrogen
Figure 2. Mean levels (with lower 95% conﬁdence intervals) of (A)
follicle-stimulating hormone (FSH), (B) immunoreactive inhibin (IR-INH),
(C) inhibin A, (D) inhibin B, and (E) estradiol as a function of menopausal
status. Group 1: premenopausal, without any change in menstrual cycle
pattern; group 2: early perimenopausal, with a reported change in cycle
frequency but experiencing menses in the preceding 3 months; group 3:
late perimenopausal, with no menses in the preceding 3–11 months; group
4: postmenopausal, with no menses for more than 12 months. Values with
the same superscript (* or †) are not statistically different; values with
differing superscripts are signiﬁcantly different, P < 0.05 [90]. Reproduced
from Burger et al. [98]. Copyright Blackwell Science Ltd.
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environment because the increased estrogen levels enhance
tumor growth in patients with estrogen receptor-positive BC.
Preclinical and clinical studies may help elucidate the
underlying mechanisms of the potential ZOL-mediated
anticancer activity observed in women with a low-estrogen
environment and thus help deﬁne the subpopulation of
patients mostly likely to beneﬁt from adjuvant ZOL therapy.
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